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Implementation of mifepristone medical
abortion in Canada: pilot and feasibility
testing of a survey to assess facilitators and
barriers
Courtney Devane1,2, Regina M. Renner1,3, Sarah Munro1,3, Édith Guilbert1,4, Sheila Dunn1,5,
Marie-Soleil Wagner1,6 and Wendy V. Norman1,3,7,8*
Abstract
Background: Direct primary care provision of first-trimester medical abortion could potentially address inequitable
abortion access in Canada. However, when Health Canada approved the combination medication Mifegymiso®
(mifepristone 200 mg/misoprostol 800 mcg) for medical abortion in July 2015, we hypothesized that the restrictions
to distribution, prescribing, and dispensing would impede the uptake of this evidence-based innovation in primary
care. We developed and pilot-tested a survey related to policy and practice facilitators and barriers to assess
successful initiation and ongoing clinical provision of medical abortion service by physicians undertaking
mifepristone training. Additionally, we explored expert, stakeholder, and physician perceptions of the impact of
facilitators and barriers on abortion services throughout Canada.
Methods: In phase 1, we developed a survey using 2 theoretical frameworks: Greenhalgh’s conceptual model for
the Diffusion of Innovations in health service organizations (which we operationalized) and Godin’s framework to
assess the impact of professional development on the uptake of new practices operationalized in Légaré’s validated
questionnaire. We finalized questions in phase 2 using the modified Delphi methodology. The survey was then
tested by an expert panel of 25 nationally representative physician participants and 4 clinical content experts.
Qualitative analysis of transcripts enriched and validated the content by identifying these potential barriers:
physicians dispensing the medication, mandatory training to become a prescriber, burdens for patients, lack of
remuneration for mifepristone provision, and services available in my community. To assess the usability and
reliability of the online survey, in phase 3, we pilot-tested the survey for feasibility.
Results: We developed and tested a 61-item Mifepristone Implementation Survey suitable to study the facilitators
and barriers to implementation of mifepristone first-trimester medical abortion practice by physicians in Canada.
(Continued on next page)
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Conclusions: Our team operationalized Greenhalgh’s theoretical framework for Diffusion of Innovations in health
systems to explore factors influencing the implementation of first-trimester medical abortion provision. This process
may be useful for those evaluating other health system innovations. Identification of facilitators and barriers to
implementation of mifepristone practice in Canada and knowledge translation has the potential to inform
regulatory and health system changes to support and scale up facilitators and mitigate barriers to equitable
medical abortion provision.
Keywords: Mifepristone, Canada, Abortion, Survey, Family planning, Family physician, Delphi approach, Diffusion of
Innovation, Implementation science
Background
Abortion health services are safe, common, and legal in
Canada [1]. The rate of induced abortion is approxi-
mately 14–15/1000 females aged 15–44, annually [2, 3].
In Canada, abortion is a publicly funded service. Abor-
tion services are accessed in Canada either by self-
referral to an abortion/reproductive health care facility
or through a referral from their family physician to an
abortion provider [4, 5]. In 2016, surgical terminations
represented 94.7% of all first-trimester abortions across
the country [2]. In Canada, geography is a significant
barrier to accessing abortion facilities; for example, in
the province of British Columbia, 90% of all abortions
are provided in large urban cities, despite the fact that
43% of reproductive-aged women live outside these
metropolitan areas [6]. Having abortion services limited
to urban centers significantly impacts access to care for
almost half of the population of reproductive-aged
women in Canada [4].
One solution to increase equity in access to abortion is
through the provision of first-trimester medical abortion
in primary care settings. In 2005, the World Health
Organization (WHO) added mifepristone (RU 486) to
their list of essential medications, naming mifepristone
the gold standard for first-trimester medical abortion
care [7]. In high-income countries, the implementation
of mifepristone has been associated with an increase in
the proportion of abortions performed as medical abor-
tions [8–11]. However, rates of mifepristone implemen-
tation have differed greatly internationally [9, 10, 12–14].
Emerging evidence from Australia and the USA sug-
gests that variations in access to mifepristone may be
due to the differences in health systems, provider train-
ing and supports, financial barriers, and legal restrictions
[15–17]. For example, in the USA, mifepristone may be
dispensed only by the prescriber and not by a pharma-
cist. Ten years after the introduction of mifepristone in
the USA, first-trimester medical abortions only repre-
sented 36% of all abortions compared to over 80% of
first-trimester abortions in many European countries
[10, 18]. Furthermore, in Australia, where pharmacists
may dispense mifepristone, women must pay $560 AUD
upfront and attend a mandatory follow-up visit 1 week
later [17], and abortion remains legally restricted or pro-
hibited in some jurisdictions [19–21].
In July 2015, Health Canada approved Mifegymiso® (a
combination product containing mifepristone 200 mg
and misoprostol 800 mcg) for medical abortion, making
Canada the 63rd country to approve the medication
since 1988 [22, 23]. In 2016, the Society of Obstetricians
and Gynecologists (SOGC) published new Canadian
clinical practice guidelines for medical abortion [24],
prior to commercial availability of the product. However,
the initial approval of mifepristone in Canada stipulated
restrictive constraints that did not conform with the
clinical guidelines or usual clinical practice including
distribution of the medication only directly to physicians
and pharmacists who had completed a certified training
program and registered with the licensed distributor,
prescribing and dispensing limited to these certified phy-
sicians, ultrasound required for gestational dating prior
to administration, physician observation of patient inges-
tion of mifepristone, and use up to only 49 days gesta-
tional age [22]. These stipulations were not consistent
with the extensive evidence on safety and effectiveness
for this medication. Family planning experts deemed the
restrictions unnecessary [24, 25].
We hypothesized that these federal regulations would
restrict patient access by impeding the uptake of mife-
pristone abortion practice, particularly for those profes-
sionals working in primary care, such as family
physicians who are not primarily abortion providers,
pharmacists, nurse practitioners, and midwives who have
a critical role to play in expanding access to abortion
services beyond large urban settings. We were unable to
identify a survey instrument that comprehensively ex-
plored factors influencing the implementation of medical
abortion practice. Prior to January 2017 when mifepris-
tone became available in the Canadian market, we devel-
oped and pilot-tested a survey to investigate health
policy, health system, and health care delivery factors
that influenced the uptake and implementation process
for mifepristone first-trimester medical abortion prac-
tice. Our objectives were to develop a survey instrument
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informed by a theoretical framework (phase 1), validate
the survey content using qualitative group interview data
(phase 2), and pilot test the usability and readability of
the survey in an online format for feasibility (phase 3).
Our goal was to understand how policy and practice
characteristics relate to access to abortion services
throughout Canada.
Methods
We conducted this Mifepristone Survey Development
Study as one component of our larger mixed-methods
study, Mifepristone Implementation Research in Canada
[26]. This comprehensive study examines the health pol-
icy, system, and service facilitators and barriers affecting
the initiation and ongoing provision of medical abortion
services in Canada [26]. Our data collection for the
mixed methods study includes the following: (A) surveys
with pharmacists and prescribers at baseline, 6 months
and 1 year following the introduction of mifepristone
medical abortion to their practice; (B) interviews with
pharmacists and prescribers; (C) interviews with policy
and health system stakeholders; (D) creation of an online
community of practice platform to detect and support
policy, system, and practice challenges; and (E) the
evaluation of continuous integrated knowledge transla-
tion with health policy, system, and service decision-
makers and health professional organizations (i.e., co-
production of evidence by researchers and decision-
makers). In this paper, we report the development
process for the prescriber’s survey (data collection
method “A”).
Our survey development process involved three phases
that occurred between July 2015 and January 2017: (1)
development of preliminary survey items [group I], (2)
content validation via a modified Delphi process with a
panel of physician experts [group II], and (3) pilot test-
ing of the draft survey for reliability and usability in an
online format [group III]. In phase 2, the panel of phys-
ician experts also provided their perceptions of the im-
pact of facilitators and barriers on abortion services
throughout Canada which further informed the content
we aimed to cover in our survey instrument. This study
was conducted by the members of the Contraception
and Abortion Research Team—Groupe de recherche sur
l’avortement et la contraception (CART-GRAC), a na-
tional, interdisciplinary, cross-sectoral collaboration en-
gaging in research to support the provision of health
services and implementation of policies that ensure
equitable access to high-quality family planning know-
ledge, methods, and services for women and families
throughout Canada [27]. Ethics approval for this study
was obtained from the University of British Columbia
Children’s and Women’s Hospital Research Ethics Board
for research involving human subjects (H15-03207).
Phase 1: Development of preliminary survey items
The development of the survey question constructs was
guided by two conceptual frameworks: (1) Roger’s Theory
of the Diffusion of Innovation as conceptualized by
Greenhalgh et al. [28], which describes the determinants
for implementation of innovations in health service de-
livery and has been used previously in Canada to under-
stand the implementation of task-shifting contraceptive
care from physicians to nurses [29]; (2) Godin framework
[30], which integrates the Theory of Planned Behavior
[31] and Triandis’ Theory [32] to predict an individual’s
intention and uptake of clinical behavior. Greenhalgh’s
framework posits that the interaction between the
innovation, the intended adopter(s), and a particular
context influences diffusion, dissemination, and imple-
mentation. The Greenhalgh framework consists of nine
constructs: characteristics of the innovation and adopter,
methods of diffusion and dissemination (e.g., communi-
cation and influence), system antecedents and readiness,
outer context (e.g., external influences), resource systems
and change agents (e.g., administrators, public health
agents, public advocates), and the role of these con-
structs in facilitating the implementation process [28].
Légaré’s validated instrument [33] is based on the Godin
framework [30] and assesses the impact of professional
development on the uptake of new practice by measur-
ing the following constructs: belief about capabilities, so-
cial influences, and beliefs about consequences, moral
norms, and intentions. This framework has good appli-
cation to practice in the abortion context, where role
identity, moral norm, and social factors could have a
strong influence on behavior. Figure 1 identifies these
constructs and the dimensions by which each construct
can be evaluated for the innovation’s adoption within
the health system. Because mifepristone is a new ap-
proach to medical abortion services in a Canadian
context, Godin and Greenhalgh’s frameworks fit concep-
tually with the goals of our survey.
Based on the conceptual frameworks above and previ-
ous work [34, 35], in October 2015, 4 of our clinician-
researchers who are experts in abortion care (group I:
RR, WVN, SD, EG) created a survey instrument with 47
baseline questions and 21 follow-up questions. The ques-
tions were developed to assess facilitators and barriers to
the adoption of mifepristone into practice as well as the
impact of mandatory training on the practice of mifepris-
tone medical abortion. This occurred prior to the January
2017 market availability of mifepristone. The clinician-
researchers identified key questions in a recursive fashion
until consensus was reached. Constructs were restricted
based on the relevance to abortion practice in Canada.
The divisions of questions among Greenhalgh’s domains
were as follows: Outer Context (n = 11), System Anteced-
ents for Innovation (n = 6), Characteristics of the
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Innovation (n = 10), System Readiness for Innovation (n =
7, including 3 “matrix-style” questions with 32 response
boxes combined), Adopter/Assimilation (n = 6), and Com-
munication and Influence (n = 11) plus 15 demographic
questions and 2 open-ended questions. An example of
how questions were mapped to each domain of Green-
halgh’s conceptual framework is depicted in Table 1. Two
Greenhalgh domains, Characteristics of the Innovation
and Outer Context, include stigma and harassment. Ques-
tions exploring physician attitudes toward and experiences
with abortion, including stigma and harassment, were
measured using the validated instrument developed by
Harris et al. [36, 37]. The clinician-researchers chose not
to include questions pertaining to Greenhalgh’s domain
“Implementation” at baseline and opted to explore this
construct in 6-month and 12-month follow-up surveys.
Phase 2: Content validation
Participants
Physician experts in sexual and reproductive health
[group II] were invited to participate in group interviews
to examine face and content validity of the first version
of the survey instrument developed by group I, using a
modified Delphi method [38]. Group interviews took
place over a 5-week period in January and February
2016. Criteria for inclusion were holding a current pro-
fessional license to practice as a physician in at least one
Canadian jurisdiction and willingness to participate.
Emailed invitations were circulated via professional sex-
ual and reproductive health care networks, among physi-
cians who were current abortion providers and also
among primary care and specialist physicians known to
be involved in women’s reproductive health care who
might consider providing abortion in their practice. A
follow-up email was sent out 7 to 10 days after the first
contact. Panelists in group II were encouraged to invite
eligible colleagues to participate through a snowball
sampling approach. We received 28 replies, and each
participant received a copy of the consent form in ad-
vance and had at least 1 week to decide if they wished to
participate. There were 3 panelists who were unable to
attend in-person or through teleconferencing. Each of
the 25 final panelists received a $200 honorarium for
their 2.5 h of time.
Data collection
The Delphi method is a process that structures commu-
nication among large groups of individuals to collectively
obtain an expert opinion for a valid and useful result
[39]. The Delphi approach is used widely in research
where the research problem “does not lend itself to pre-
cise analytical techniques but can benefit from subjective
judgments on a collective basis” [40]. This approach en-
abled us to involve a representative panel of expert
abortion practitioners, non-provider physicians, and
physician-researchers from across the country, stratified
by province, to discuss and validate the preliminary sur-
vey questions. The Mifegymiso® product label and asso-
ciated regulations were publicly available, but not widely
disseminated as the product was not yet on the market.
Thus, prior to focus group data collection, panelists had
minimal knowledge of how mifepristone was likely to be
implemented in Canada.
Fig. 1 A conceptual model of diffusion of innovations in health service delivery and organizations, adapted from Greenhalgh et al. [28]
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A distinct characteristic of the Delphi method is the
sequential, staged approach, whereby panelists are in-
volved in subsequent “rounds” [41]. We modified this
approach by involving group II in just one round be-
cause the goal of our group interviews was to collect
important input and not to reach consensus. Further-
more, between each group interview, we revised the sur-
vey instrument to reflect the input provided by the
previous group. A final version of the survey instrument
was created after all five group interviews. Each group
Table 1 Example of mapping questions to domains of Greenhalgh (“Outer Context” domain shown below)
Greenhalgh’s
aspects
Question Response
options
Aspect Factor
Regulatory
federal
Health
system
provincial
Health
services
community
facility
Practice
community
attitudes
Facilitator Barrier
Incentives and
mandates
Have you previously ordered
and stocked at your office or
facility any medications for sale
to your patients? (samples not
applicable)
Yes
No
X National
regulatory
support for
abortion (CMA
code of ethics)
MD office to
buy and
stock
medication
Inter-
organizational
norm setting
and networks
Who will be responsible for
ordering mifepristone at your
facility?
I will be
The medical
director or
another
physician
A pharmacist
at our facility
or in our
community
A non-
physician,
non-
pharmacist
staff member
No one will
take
responsibility
under current
regulations
Uncertain at
this time
[please
elaborate]
Other [please
elaborate]
X Provincial
regulatory
support for
abortion
(licensing)
Physician
office to buy
and stock
medication
Will you travel to provide
medical abortion? (i.e., outside
the community where you
primarily practice)
Yes
No
X
If “yes” to 19, how far is the
community where you will
provide medical abortion from
your home?
[number] km X
If “yes” to 19, how will you
travel?
Road
Ferry
Air
X
Please indicate the number of
women per month you
currently see for abortion who
travel for 3 h or more to reach
your service.
[number] X Distance
between
woman and
abortion
service
Are there abortion services
currently available in your
community?
Surgical
abortion
Medical
abortion
Both
Neither
X Established
community or
facility
mandate
The
community
may have
no prior
abortion
services
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consisted of three to six expert panelists led by at least
two experienced moderators who were research team
members (WVN, RR, SD). Group interviews were con-
ducted face-to-face or through video conference and
began with a brief overview of the proposed regulation
for mifepristone in Canada as well as an introduction to
the research project. First, discussions guided by a semi-
structured interview guide (see Table 2) were audio-
recorded and then transcribed. Using a modified Delphi
approach, drafts of the survey were distributed for expert
opinion and review during each group interview. Expert
panelists [group II] reviewed each question on the first
version of the survey instrument for clarity and rele-
vance. Survey questions and response options were pre-
sented individually on a PowerPoint slide. Panelists were
invited to give feedback on the question wording and
the rationale for their suggestions, suggest non-essential
questions to be removed, provide feedback on whether
or not the proposed questions would capture address-
able barriers and facilitators for dissemination, and sug-
gest appropriate sub-dimensions and items to ensure
that the questions captured relevant elements of our
conceptual frameworks and provided appropriate re-
sponse options. We allowed time for open-ended discus-
sion for panelists to share their perceptions, attitudes,
and beliefs regarding barriers and facilitators to mifepris-
tone implementation, including identification of add-
itional factors that should be explored in the survey.
Panelists were given the option to submit written com-
ments to maintain anonymity. Questions that were more
challenging to articulate were presented first in each
group. Between group interviews, questions were refined
to ensure we were adequately capturing information
relevant to different practices and communities in a lo-
gical progression. The audio recording from each group
interview was transcribed digitally by a transcriptionist
adhering to confidentiality.
Analysis
Our team facilitators (WVN, RR, SD) reviewed the
group interview transcripts several times independently
to identify emerging themes. Together, they conducted a
content analysis using the data collected from the group
interviews in a recursive fashion to identify common and
conflicting viewpoints in a stepwise analysis. Similarities
and differences across the sub-groups (i.e., rural versus
urban practice setting, specialty practice versus primary
care, current abortion providers versus potential new
providers) were also explored. The aim of our analysis
was to ensure that questions of the survey instrument
were relevant, understandable, provided clear answers,
and included the range of relevant factors related to
physician initiation and ongoing provision of mifepris-
tone medical abortion practice.
Step 1: Usability Step 1 of the analysis involved an it-
erative process of identifying and itemizing potential
changes to the format of the survey questions. This in-
cluded a thorough review of comments from the group
interviews about which survey questions were clear, con-
cise, and comprehensive, and which questions required
additional editing. As Fowler [38] suggests, “Poor ques-
tion design is pervasive, and improving question design
is one of the easiest, most cost-effective steps that can
be taken to improve the quality of survey data” (p. vii).
For example, each focus group provided feedback on the
importance of consistency between Likert scale rating
response directions throughout the survey, i.e., from
strongly disagree to strongly agree, from less to more,
from harmful to beneficial, or from extremely difficult to
extremely easy. Other discussions involved clarifying
ambiguous terms or concepts and the potential conse-
quences of response alternatives for participant answers.
For example, to understand the degree of burden a phys-
ician will experience if they are required to sell mifepris-
tone directly to patients at their facility, we initially
asked about the cost of stocking the medication. How-
ever, two key concepts in this question were identified:
“burden” and “cost.” We therefore went on to distin-
guish both “cost” burden and the “administrative” bur-
den of ordering and maintaining stock. Panelists
employed at private clinics suggested they would be
Table 2 Focus group instructions for question analysis
Prompts for individual items in the questionnaire
1. How did you find the wording of the question?
2. What are your thoughts on the purpose of the question? Elaborate
if necessary: “purpose” as in “what is the question trying to ask?”
3. What are your thoughts on the correlation between the question
and the options listed for that question?
4. Were there any options that you would like to have responded to
but were not listed in the question? If so, what were these options?
5. Were there any options that you feel were unnecessary? If so, what
were these options?
After all items from the questionnaire have been completed, the
panelists will engage in a general feedback section comprised of the
following questions.
Prompts for general feedback for the questionnaire
1. What were the strengths of the questionnaire? What were the
weaknesses of the questionnaire?
2. Was the questionnaire presented in a logical manner? If not,
what would be a more logical progression for the questionnaire?
3. Were there any missing topics of questions that you feel may be
beneficial for our study? Please elaborate.
4. If you were requested to complete this survey in the community,
are there any barriers that would prevent you from completing the
survey?
5. Other comments?
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considering the high purchase cost as part of the over-
head of keeping stock (estimated at $300 per dose). Con-
versely, panelists employed in settings that already sell
contraceptives reported that they would experience no
burden themselves, but that it was likely their patients
would, due to the high cost.
Step 2: Content and context The second step of the
analysis involved a general inductive approach to under-
stand the necessary content modifications to the ques-
tions and response options. For example, each focus
group engaged in the discussion about the definition of
the term “community.” A participant employed in a rural
setting explained that “community” does not accurately
represent the vast geographic population catchments
that rural and remote physicians typically serve: “I’m
looking at women that are a two-to-three-and-a-half-
hour flight away from me, that are in my ‘service region’”
(focus group 2, family doctor, rural). Conversely, a par-
ticipant employed in an urban setting stated, “If I have
to drive for more than 10 minutes, I’m outside of my
community” (focus group 4, OB-GYN, urban). As poorly
defined terms can negatively impact the reliability of
participants’ responses, we edited and replaced ambigu-
ous terms or jargon based on panelist feedback. This in-
cluded defining terms in the wording of the question or
asking supplementary questions (e.g., How far from your
home is the community where you will provide medical
abortion?).
Several additional questions were suggested by the
panelists that did not contribute to the goals for the
study or fit within the survey’s conceptual framework.
For example, panelists suggested to include questions re-
lated to patient satisfaction or to conduct an economic
analysis comparing surgical abortion to mifepristone
medical abortion. These questions were not included to
ensure the final survey met the aims of the research
question [26]. Following all group II input and the asso-
ciated analysis, a second version of the survey instru-
ment was iteratively reviewed by group I until consensus
was reached and the indicated domains in the theoretical
frameworks were represented by appropriate questions.
Step 3: Thematic analysis of facilitators and barriers
In order to ensure that our survey instrument captured
relevant perceived barriers and facilitators to implemen-
tation of mifepristone, we also conducted a thematic
analysis of group interview transcripts, informed by crit-
ical realist principles—that is, we explored how panelists
made meaning of their abortion provision intentions and
experiences and the ways that social context informed
them, while considering the material reality in which
mifepristone would be implemented in Canada [42]. The
purpose of conducting a thematic analysis of the group
interview data was to enhance the development of the
survey instrument. One qualitatively trained researcher
(CD) read the transcripts to become immersed in the
data and identify patterns across panelists and groups.
She independently developed a codebook of initial cat-
egories related to panelists’ perceptions of barriers and
facilitators to implementation of mifepristone, following
these phases: (1) initial coding for candidate categories
and patterns in the transcripts, (2) focused coding for
main categories and patterns, and (3) reviewing and re-
fining categories. This nurse-researcher was not involved
in the data collection phases, which helped to facilitate a
data-driven inductive approach as she did not share the
same assumptions and analytic preconceptions as to the
other members of the research team, who were experts
in family planning research. She coded the transcripts
independently and discussed her analysis at weekly inter-
vals with a postdoctoral fellow (SM) with expertise in
qualitative methods who had been involved in designing
the protocol and data collection. Together, they engaged
in a reflexive dialog about the emerging categories, the
significance of the categories, the convergence and in-
consistencies between the groups [43], and the conse-
quent implications for facilitating or impeding access to
mifepristone medical abortion. Together, they wrote the
results of the analysis into a rich, descriptive narrative.
All analysis was conducted in Microsoft Word.
Finalizing the survey procedure
The second version of the survey instrument was dir-
ectly translated in French using a translation service.
The Francophone investigators on our team (EG, MSW)
reviewed the translated survey for content and face val-
idity to ensure the correct translation of medical termin-
ology and relevance for Francophone physicians.
Following the translation, the survey instrument was
entered, in both English and French, into a Research
Electronic Data Capture (REDCap) platform, a secure
web-based meta-data-driven application, housed at our
research institution [44]. Branching logic was used to de-
termine the respondents’ pathway in the survey. This
mitigated the potential for survey fatigue by ensuring
questions were relevant based on variables in responses.
Phase 3: Pilot testing
To assess usability and reliability of the online survey,
we invited the 9 physician co-investigators on the wider
study, who were not involved in phase 2 content valid-
ation, to pilot test the second version of the survey in-
strument [group III]. To support rigor, conducting a
pilot test with participants who are representative of the
study sample interests is recommended [38, 45]. Each
physician co-investigator was emailed a link to the RED-
Cap survey in December 2016 to January 2017 and was
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given instructions to complete the survey and respond
by email with recommendations. Our team revised the
online survey in real time as recommendations from
group III were received. This iterative cycle of testing,
revising, and retesting the survey identified fewer issues
in each subsequent co-investigator response until no fur-
ther issues remained. The English survey link was tested
139 times and the French survey link was tested 43
times among group III, and finally by all members of
group I, during this phase.
Results
Development of preliminary survey items (phase 1)
The first version of the survey instrument consisted of
68 questions involving demographic and practice charac-
teristics (22 questions), previous experience providing
abortion services (8 questions), theoretical domains from
Greenhalgh’s framework (24 questions), and the 12-item
questionnaire adapted from Légaré’s validated instru-
ment [27]. The Légaré instrument questions applied to a
range of content areas; therefore, very few wording
changes were required (see Table 3). Appropriate ques-
tions stemmed from 3 previously developed and fielded
instruments developed by CART for the diffusion of
contraception practice innovations [34, 35, 46] with
minor modifications (e.g., “mifepristone” replacing
“contraceptive” where appropriate).
Results of expert content validation (phases 2 and 3)
Expert panelists [group II] in phase 2 (n = 25) who par-
ticipated in a total of 5 group interviews represented
physicians who provided abortion and those who had
not, from primary care and specialty practice settings,
rural and urban communities, in 3 provinces and 2 terri-
tories (British Columbia, Ontario, Nova Scotia, North
West Territories, and Yukon) including those trained as
family physicians and obstetrician gynecologists (see
Table 4). After phase 2, 5 clinical content experts (which
included representation from the fourth province, Que-
bec) finalized the Mifepristone Implementation Survey
to distribute for pilot testing. Group III participants in-
volved in the final phase of development provided repre-
sentation from additional 3 provinces (Alberta,
Manitoba, and Quebec). By phase 3, the survey length
increased from 47 baseline questions to 65 baseline
questions which addressed Greenhalgh’s domains: “Sys-
tem Readiness for Change” (n = 19), “Outer Context”
(n = 21), and “System Antecedents for Innovation” (n =
25). This increase was as a result of feedback received
during phase 2, in which expert panelists [group II]
Table 3 Continuing professional development questionnaire (adapted from Légaré et al. [33])
1 I intend to provide medical abortion. Strongly disagree Strongly agree
1 2 3 4 5
2 To the best of my knowledge, the percentage of my colleagues who provide medical abortion is: 0–20%, 21–40%, 41–60%, 61–80%, 81–100%
3 I am confident that I could provide medical abortion if I wanted to. Strongly disagree Strongly agree
1 2 3 4 5
4 Providing medical abortion is the ethical thing to do. Strongly disagree Strongly agree
1 2 3 4 5
5 For me, providing medical abortion would be: Extremely difficult Extremely easy
1 2 3 4 5
6 Now think about a co-worker whom you respect as a professional. In your opinion, does he/she
provide medical abortion?
Never Always
1 2 3 4 5
7 I plan to provide medical abortion. Strongly disagree Strongly agree
1 2 3 4 5
8 Overall, I think that for me providing medical abortion would be: Useless Useful
1 2 3 4 5
9 Most people who are important to me in my profession provide medical abortion. Strongly disagree Strongly agree
1 2 3 4 5
10 It is acceptable to provide medical abortion. Strongly disagree Strongly agree
1 2 3 4 5
11 I have the ability to provide medical abortion. Strongly disagree Strongly agree
1 2 3 4 5
12 Overall, I think that for me providing medical abortion would be: Harmful Beneficial
1 2 3 4 5
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identified several questions where division into 2 individ-
ual questions improved clarity. For example, a partici-
pant suggested, “I guess maybe the question is, you
might have one [an ultrasound] in your facility but if
you’re not trained to use it, do you have somebody who
can do it?” (focus group 4, OB-GYN, urban). This is an
example of how questions related to practical implica-
tions and to constructs from Greenhalgh’s framework
[24]. For this participant, it was more meaningful to ask
about access to a skilled ultrasonographer as a potential
barrier rather than if they had an ultrasound machine in
their facility.
Consideration of rural and urban differences was key
in validating response options. For example, open-ended
responses suggested that practitioners in rural settings
defined community very broadly in comparison with
practitioners in urban centers: “I think 15 kilometers is a
pretty urban number” (focus group 1, OB-GYN, rural).
Similarly, practitioners employed in hospital-affiliated
abortion facilities were less concerned about ordering,
stocking, or selling medications than their colleagues in
private offices or clinics: “Our hope is that it will be on
our hospital formulary and that it be at no cost to the
patient” (focus group 5, family physician, urban).
Perceptions of potential barriers and facilitators to
mifepristone implementation
Analysis of group interviews led to our identification of
categories that represent physicians’ and abortion ex-
perts’ perceptions of potential barriers and facilitators to
the implementation of mifepristone in Canada. None of
the categories discussed was characterized as facilitators;
the key categories that emerged from the analysis of the
group interview transcripts included the following bar-
riers: physicians dispensing the medication, mandatory
training to become a prescriber, burdens for patients, lack
of remuneration for mifepristone provision, and services
available in my community. This qualitative data further
Table 4 Characteristics of focus group panelists (group II)
Focus group 1
(n = 5)
Focus group 2
(n = 6)
Focus group 3
(n = 5)
Focus group 4
(n = 6)
Focus group 5
(n = 3)
Total, n
(%)
Discipline
Family practice 3 4 3 2 2 14 (56%)
Obstetrics-gynecology (OB-GYN) 2 2 2 4 1 11 (44%)
Experience* (years)
No abortion experience 1 1 1 3 (8%)
Less than 5 1 1 1 1 4 (15%)
5–9 1 1 2 (13%)
10–19 2 2 1 4 (15%)
20+ 3 2 1 6 (24%)
Primary practice type
Hospital 2 2 1 3 2 10 (40%)
Clinic 2 1 1 3 1 8 (32%)
Primary care 2 3 5 (20%)
Gender
Male 2 2 6 10 (40%)
Female 5 4 3 3 15 (60%)
Province
British Columbia 5 4 5 14 (56%)
Ontario 6 2 8 (32%)
Nova Scotia 1 1 (4%)
Territories 2 2 (8%)
Setting
Urban 5 3 6 2 16 (64%)
Rural 6 2 1 9 (36%)
Total 25 (100%)
*Experience refers to the number of years the participant has been providing abortion services (medical, surgical, or both) after post-graduate training; numbers
may not add up to 100% due to incomplete data
Devane et al. Pilot and Feasibility Studies           (2019) 5:126 Page 9 of 14
supported and enriched the expert content validation by
clarifying and validating the questions and response
options.
Burdens for patients Group panelists (group II) empha-
sized that having medical abortion services in primary
care in remote communities would be important to en-
sure that patients can remain close to home. Rural phy-
sicians from one focus group identified potential
revisions to the survey to reflect the reality of providing
family planning services in remote communities that
serve vast catchment areas and have limited resources
for surgical backup in the event of a failed first-trimester
medical termination. As one physician from the far
north clarified, a question could explore, “If I’m in a big-
ger [rural] community like I am, I am the abortion pro-
vider, ‘What communities do [you] service and how far
[away] are the women that are potentially seeking that
help?’” She went on to explain that her large community
serves “women that are a 2 to 3 ½ hour flight away”
(focus group 2, family doctor, rural). Panelists also per-
ceived that the federal requirement for patients to sign
mandatory consent forms and be observed while ingest-
ing the medication was “so insulting to women” (focus
group 1) and excessive in comparison with other treat-
ments: “I suspect you sign fewer forms if you’re going
for cardiovascular surgery” (focus group 1).
Physicians dispensing the medication Panelists ob-
served that the federal restriction for “physician-only
(not pharmacist) dispensing” of mifepristone would be a
key barrier in primary care settings, compared to
purpose-built abortion facilities or hospitals. The re-
quirement that a physician dispenses medication in place
of the medication being available to purchase at a phar-
macy is highly unusual in a Canadian context. This
would require physicians interested in prescribing mife-
pristone, to set up the infrastructure to stock and sell
the medication: “So it’s sort of a two-pronged thing. One
is additional cost associated with the actual selling of the
prescription to the patient like a dispensing fee, what-
ever. The other is capital cost to be able to sell it. So the
cabinet maker, and the fees for the credit card machine”
(focus group 4, OB-GYN, urban). Most physicians’ of-
fices do not have such infrastructure, which led panelists
to engage in discussion about what, hypothetically, this
new practice change might look like: “And this is a lot of
money. Like what would people do? Take VISA? I mean
it does raise logistical questions, right?” (focus group 4,
family physician, urban). Physician-only dispensing also
may prevent patients from filling their prescriptions at a
convenient time and location: “That in itself is a burden,
if you have to wait for the pharmacy to courier it back
[to the physician]. You’ve only got a certain time. Are
you going to put her out in the waiting room and see
someone else or?” (focus group 3, OB-GYN, rural, expe-
rienced provider).
Mandatory training to become a prescriber In
Canada, physicians are expected to maintain skills and
competency through self-study and continuing profes-
sional development. Panelists’ comments indicated that
the unique requirement of completing a mandatory
training program, only for this medication, and to regis-
ter with the manufacturer may discourage physicians
and pharmacists to adopt medical abortion practice and
patients would have limited access to qualified providers.
As one participant described: “But if you go in there and
the [trained] person isn’t working that day, or has to be
sick, or on holidays, or anything else and nobody else
can fill that stupid prescription?” (focus group 3, family
physician, urban). It also may mean that trained physi-
cians would face the burden of being a solo abortion
provider: “I can’t see a bunch of people doing all the
training. Like, I anticipate it’s going to put more of a
burden on smaller numbers of people.” (focus group 2,
family physician, rural).
Lack of remuneration for providing medical abortion
The lack of existing remuneration structures (e.g., billing
codes) for medical abortion was identified as another
critical barrier. As one experienced abortion provider
clarified, providers would have to cobble together differ-
ent fees to adequately cover the costs of providing this
service: “As you say, if somebody does not, they will bill
whatever they can do in the way of a counselling fee, a
physical examination, et cetera, and so the question is,
‘Is that going to be adequate?’ So, if we’re going to do it,
you might want to just say straightforwardly, ‘In your
jurisdiction, are you paid well enough to cover your
costs?’” (focus group 1, family physician, urban). She and
other experienced providers noted that low fees for med-
ical abortion could be a deterrent for new providers and
their practices: “But my point is, automatically there’s a
cost. It’s whether it’s enough of a barrier for you to pro-
vide it or not.” (focus group 3, family physician, urban).
Services available in my community Finally, panelists’
feedback illuminated the barriers associated with having
limited resources to support the provision of medical
abortion. Timely access to ultrasound was a particular
challenge for small rural communities, as one participant
described: “Yeah, so I mean in smaller towns ultrasound
is not – it’s really – we have a bedside ultrasound in
Emergency, but there’s no other ultrasound in town
available outside of the hospital. Then in [larger town]
there’s community ultrasound place, but they’re not gen-
erally run – You know, they’re like business hours right”
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(focus group 5, family physician, rural). Further, in both
urban and rural sites, some panelists described having
limited support from surgeons in the rare event of a
failed termination or complication that requires surgery.
While colleagues may provide support if “the person is
unstable or it’s an emergency, or they have to, ‘those’
people who don’t want to be involved in terminations
will choose not to be involved” (focus group 3, OB-
GYN, rural). Limited collegial support can be a deterrent
for new abortion providers, who may not wish to strain
their interprofessional relationships by introducing abor-
tion to their scope of practice.
Results of pilot testing (phase 3)
In phase 3, 1 round of surveys was administered via
REDCap and distributed for readability and usability
testing through an online link that included modifica-
tions based on the feedback from the larger CART-
GRAC network (group III). The second version of our
survey instrument consisted of 9 demographic questions,
52 questions mapped to Greenhalgh’s conceptual model
(see Table 1 for an example), the 12-item questionnaire
adapted from Légaré’s validated instrument, and 17
open-ended questions that provided respondents with
the option to elaborate their responses. During phase 3,
minor technical changes took place including spelling
errors, changing the order of demographic questions,
improving the clarity of partner logo images, and moving
hyperlinks to resources to the end of the survey. Once
each of the technical changes was addressed, we estab-
lished our final survey instrument.
Between phases 2 and 3 of the Mifepristone Imple-
mentation Survey Development Study, Health Canada
removed the requirement for physician observation of
the patient swallowing mifepristone (October 2016, prior
to market availability in January 2017). This change was
due in part to the early dissemination of our focus group
finding that observation would create an unnecessary
burden for patients [47–49]. However, package labeling
in the marketed product did not reflect this change until
September 2017. Our research team made the decision
to include the questions we had developed and tested in
focus groups around physician observed dosing to cap-
ture the impact of a regulatory change not necessarily
reflected physically on the packaging materials and on
physician knowledge and practice.
Discussion
We undertook a rigorous process to develop and pilot
test a survey instrument to investigate the health policy,
health system, and health care delivery factors impacting
first-trimester mifepristone abortion practice in Canada.
In phase 1, family planning experts grounded the first
version of the survey instrument in established
theoretical frameworks. In phase 2, 5 group interviews
leveraged the expertise of reproductive health providers
from across the country and determined that Health
Canada’s proposed regulations would act as barriers to
implementation, particularly in primary care. We col-
lected initial impressions on potential barriers from a
sample population of physicians and developed a 65-
item baseline survey using 3 of Greenhalgh’s domains:
“System Readiness for Change” (n = 19), “Outer Context”
(n = 21), and “System Antecedents for Innovation” (n =
25) to pilot test. In phase 3, a larger network provided
feedback to refine the survey. The Mifepristone Imple-
mentation Survey is the result of a 3-phase process to
develop a comprehensive, nationally relevant instrument.
We intend to administer our survey with a national sam-
ple of mifepristone providers and to use our findings to
inform future medical abortion policy, health system,
and service decisions in Canada. Our larger program of
research will go on to collect 6-, 12- and 24-month
follow-up data from this prescriber survey, and from a
planned pharmacist survey, to measure the change in
practice experiences and behavior. We will tailor follow-
up survey content to focus on the constructs of Diffu-
sion of Innovations that relate to the barriers and facili-
tators we identify from the baseline survey and to
determine the uptake of mifepristone abortion practice
by respondents.
Our study process resulted in a more comprehensive
survey than any we were able to identify in the inter-
national literature to understand the barriers to contra-
ceptive and abortion service provision in high-income
countries [5, 50–52]. For example, to assess similar fac-
tors in a related field in 2011, Hulme et al. conducted 72
interviews with healthcare providers and health system
stakeholders to understand the barriers to contraceptive
use in Canada [53]. Interviews were informed by 2 vali-
dated frameworks for access and quality in family plan-
ning; however, the sample primarily included
participants from Canada’s 3 largest provinces, Quebec,
Ontario, and British Columbia, and may not have
reflected policy issues in other provinces, territories, and
between rural and urban [54]. Furthermore, in 2013,
Guilbert et al. surveyed 78 abortion facilities and their
abortion providers across Canada to understand the na-
tional availability and practice of first-trimester medical
abortion [5]. Their survey instrument, which was
adapted from USA research for the Canadian context,
investigated the facility and staff demographics as well as
clinical practice such as pre-procedure evaluation, medi-
cation regimens, and follow-up for abortion service pa-
tients [51, 52]. The survey was suitable to describe the
usual practice, but facilitators and barriers to first-
trimester medical abortion practice were not investi-
gated. This limitation was accounted for in our survey
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instrument by specifically developing questions to target
barriers to medical abortion practice identified by physi-
cians from diverse practice settings.
A significant strength in the development of this sur-
vey was the use of established conceptual frameworks
that assess multiple dimensions of implementation and
that explore physician and organizational behavior in
implementing an innovation. While Greenhalgh’s [28]
comprehensive model of diffusion, dissemination, and
implementation is based on a systematic review of em-
pirical and theoretical models, it has been criticized for
its lack of “operational definitions or measurement” for
many of the constructs (Cook et al. 2012, p. 12). Our
survey development process is an “operationalization” of
the Greenhalgh framework and applies the framework to
a health system implementation scenario.
Our study was also strengthened by group interviews
with a national expert panel representing both family
medicine and obstetrics-gynecology training, urban and
rural communities, and specialty and primary care prac-
tices. This allowed us to capitalize on the strengths of
group decision-making despite geographic separation.
The panelists’ diverse contributions enhanced the clarity
and relevance of the questions thereby ensuring high
face validity of our survey content. This exploratory ap-
proach surfaced issues that could not have been identi-
fied by our research team alone. Further, this approach
allowed us to explore physicians’ perceptions of potential
barriers and facilitators due to Health Canada’s restrict-
ive regulations for prescribing and dispensing mifepris-
tone. Physician dispensing and mandatory training were
regulatory barriers that were perceived to have the po-
tential to increase the burden on patients seeking med-
ical abortion by inhibiting physicians from implementing
mifepristone abortion care in their practices. Lack of
billing codes to support remuneration and limited avail-
ability of ultrasound and surgical backup were practical
barriers that were related to regional health system
decision-making, rather than federal medication policy.
Furthermore, Dressler et al. [54] identified barriers that
practitioners experience based on their geographic loca-
tion across Canada. They found that logistical barriers to
provision, professional isolation, and lack of replacement
providers including barriers to receive training are
uniquely identified by providers in rural and remote
communities. These concepts were validated by the ex-
pert panel as important areas to explore in the survey.
The barriers identified in this current study are investi-
gated in the survey instrument so that we may further
understand what factors influence the implementation of
mifepristone across the country.
Limitations to the Delphi approach include the poten-
tial for panelists to be influenced by the questions for-
mulated by the research team and panelists’ failure to
understand the primary purpose of the study. For ex-
ample, we did not aim for our survey to capture all po-
tential questions related to barriers and facilitators of
abortion provision in Canada, but only those most rele-
vant to mifepristone. It was challenging to balance the
length of the survey with our desire to collect adequate,
relevant information. This meant that we had to
prioritize several of the dimensions of the framework
over others, based on the relevance to our research ob-
jectives. For example, we prioritized collecting data on
barriers perceived to be addressable through health pol-
icy, system, or service delivery changes not individual at-
titudes or knowledge change.
Phase 3 pilot testing only focused on the readability and
technical aspects of the online survey instrument. We did
not include specific measurements such as Cronbach
alpha coefficients to assess internal consistency, test-retest
reliability testing, or factor analysis to describe variability
among items. However, some of the basic instruments we
used to build our survey instrument did report strong psy-
chometric testing [33].
The introduction of mifepristone and the develop-
ment of new clinical practice guidelines [24] present
an exceptional opportunity to improve women’s ac-
cess to abortion in Canada, particularly in rural and
remote areas [1, 55–57] and to improve women’s
safety and privacy by reducing the stigma and harass-
ment that can occur for women seeking a surgical
abortion [58]. To advance mifepristone practice in
Canada, health policy, system, and health care deliv-
ery implementation factors will need to be identified
to facilitate the promotion of equitable access to
abortion care. This survey will be used to assess those
barriers and facilitators of mifepristone implementa-
tion in Canada. Given that the rates of mifepristone
implementation have differed greatly internationally, it
will be crucial that barriers to practice are adequately
captured and presented to decision-makers across
Canada in a timely way.
Conclusion
The Mifepristone Implementation Survey Development
Study employed a rigorous process to develop a compre-
hensive, nationally representative survey instrument.
The specific questions were developed using frameworks
that comprehensively covered barriers and facilitators to
provider implementation of medical abortion practice.
As such, they constitute a good basis for surveys in other
jurisdictions that want to study barriers and facilitators
to medical abortion. Data from the fielding of this survey
will be used to inform decision-makers across Canada
and to facilitate more equitable access to abortion
services.
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